Arvinas
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Arvinas and other ETFs, options, and stocks.About ARVN
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.
ARVN Key Statistics
Stock Snapshot
Arvinas(ARVN) stock is priced at $10.92, giving the company a market capitalization of 698.45M. It carries a P/E multiple of -8.98.
On 2026-03-26, Arvinas(ARVN) stock traded between a low of $10.35 and a high of $11.40. Shares are currently priced at $10.92, which is +5.5% above the low and -4.2% below the high.
The Arvinas(ARVN)'s current trading volume is 531.79K, compared to an average daily volume of 1.03M.
During the past year, Arvinas(ARVN) stock moved between $5.90 at its lowest and $14.51 at its peak.
During the past year, Arvinas(ARVN) stock moved between $5.90 at its lowest and $14.51 at its peak.
ARVN News
New insider activity at Arvinas Holding Company ( (ARVN) ) has taken place on March 19, 2026. Arvinas Holding Company’s Chief Medical Officer, Noah Berkowitz,...